| Category | Key points | Best supporting citations (pqac IDs) and source (paper, year, URL) |
|---|---|---|
| Localization/Topology | Human SCO1 matches UniProt O75880 as a mitochondrial cytochrome c oxidase assembly factor in the SCO1/2 family. It is an inner mitochondrial membrane protein with a short N-terminal matrix tail and most of the polypeptide exposed to the intermembrane space, positioning its functional domain near COX2 CuA-site assembly. | (pqac-00000000, pqac-00000005) Guaragnella et al., 2024, *Int J Mol Sci*, https://doi.org/10.3390/ijms25073814 |
| Molecular function | SCO1 is the COX2-specific copper metallochaperone for cytochrome c oxidase/complex IV biogenesis. Current understanding is that it inserts copper into the CuA site of COX2 rather than catalyzing a classic enzyme reaction; its role is metallation/assembly, with redox competence of cysteines required for function. | (pqac-00000003, pqac-00000007, pqac-00000004) Garza et al., 2023, *Trends Endocrinol Metab*, https://doi.org/10.1016/j.tem.2022.11.001; Guaragnella et al., 2024, *Int J Mol Sci*, https://doi.org/10.3390/ijms25073814 |
| Copper delivery pathway | In the mitochondrial copper delivery pathway, COX17 transfers copper in the intermembrane space to SCO1, SCO2, and COX11. SCO1 and SCO2 then cooperate in CuA-site assembly on apo-COX2; one recent model describes a ternary SCO1–SCO2–apoCOX2 complex in which each SCO protein donates one copper ion. PET191/COA5 associates with SCO1 prior to copper delivery. | (pqac-00000000, pqac-00000003, pqac-00000004, pqac-00000015, pqac-00000016) Guaragnella et al., 2024, *Int J Mol Sci*, https://doi.org/10.3390/ijms25073814; Garza et al., 2023, *Trends Endocrinol Metab*, https://doi.org/10.1016/j.tem.2022.11.001 |
| Key residues/domains | SCO1 has a thioredoxin-like fold and a copper-binding CxxxC motif characteristic of SCO-family proteins; available context states that cysteine-based copper binding requires the cysteines to remain reduced. The P174L pathogenic variant lies adjacent to the copper-binding region and impairs copper transfer from COX17 despite preserved copper binding in yeast-based modeling. | (pqac-00000000, pqac-00000003, pqac-00000007) Guaragnella et al., 2024, *Int J Mol Sci*, https://doi.org/10.3390/ijms25073814; Garza et al., 2023, *Trends Endocrinol Metab*, https://doi.org/10.1016/j.tem.2022.11.001 |
| Interaction partners/complexes | Key pathway partners include COX17, SCO2, COX2, COA6, COX11, and PET191/COA5. COA6 and SCO2 are described as disulfide reductases/thiol-redox factors that maintain SCO1 and/or COX2 in a copper-binding competent state; SCO1 functions within larger complex IV assembly modules and copper-trafficking assemblies. | (pqac-00000000, pqac-00000003, pqac-00000004) Guaragnella et al., 2024, *Int J Mol Sci*, https://doi.org/10.3390/ijms25073814; Garza et al., 2023, *Trends Endocrinol Metab*, https://doi.org/10.1016/j.tem.2022.11.001 |
| Disease/phenotypes | Human SCO1 deficiency causes severe neonatal/infantile mitochondrial disease with isolated or predominant complex IV deficiency. Reported phenotypes include neonatal hepatic failure, lactic acidosis, hypertrophic cardiomyopathy/ventricular hypertrophy, hepatomegaly, encephalopathy/brain atrophy, and fatal infantile cardio-hepatic-neurologic disease. Variants reported in context include V93X, G132S, P174L, and M294V. | (pqac-00000000, pqac-00000001, pqac-00000002) Guaragnella et al., 2024, *Int J Mol Sci*, https://doi.org/10.3390/ijms25073814; Garza et al., 2023, *Trends Endocrinol Metab*, https://doi.org/10.1016/j.tem.2022.11.001 |
| Model organism evidence | Yeast studies provide much of the mechanistic evidence: Sco1 is a Cu(I)-binding mitochondrial copper protein required for COX biogenesis and CuA-site assembly on Cox2. Yeast modeling of human variants supports pathogenic interpretation, including evidence that P174L disrupts copper transfer and that SCO2 can partially complement some SCO1 defects, indicating partial functional overlap but nonredundancy. | (pqac-00000000, pqac-00000001, pqac-00000005, pqac-00000006) Guaragnella et al., 2024, *Int J Mol Sci*, https://doi.org/10.3390/ijms25073814 |
| Quantitative data/stats | Human case synthesis in the 2023 review notes 4 reported infants with SCO1 loss-of-function, all dying before 6 months, with decreased COX activity in liver and skeletal muscle and reduced COX-containing supercomplexes in skeletal muscle. In hepatocyte-specific Sco1 mouse models, median life expectancy is ~70 days; leukopenia is evident by postnatal day 27; thymus/spleen wet weights are reduced by P37 and P47; PBMC activation/death markers increase (CD44 P=0.017, annexin V P=0.003); plasma proteomics found 23 proteins increased and 133 decreased. | (pqac-00000002, pqac-00000008, pqac-00000009, pqac-00000011, pqac-00000013) Garza et al., 2023, *Trends Endocrinol Metab*, https://doi.org/10.1016/j.tem.2022.11.001; Jett et al., 2023, *J Clin Invest*, https://doi.org/10.1172/jci154684; Pioli et al., 2024, *bioRxiv*, https://doi.org/10.1101/2024.08.30.609186 |
| Recent developments 2023-2024 | Recent literature emphasizes SCO1 as part of a broader mitochondrial copper-signaling network, not just a local assembly factor. 2023-2024 work links hepatocyte-specific Sco1 loss to hepatic copper deficiency, elevated circulating copper/ceruloplasmin, AFP-dependent copper-requiring immunosuppression, and bone-marrow lymphoid progenitor defects, expanding SCO1 biology from complex IV metallation to systemic pathophysiology in mitochondrial disease models. Review/schematic updates in 2024 also refine the assembly sequence involving COX17, SCO1, SCO2, COA6, PET191, and COX2 CuA insertion. | (pqac-00000008, pqac-00000009, pqac-00000010, pqac-00000013, pqac-00000015, pqac-00000016) Jett et al., 2023, *J Clin Invest*, https://doi.org/10.1172/jci154684; Pioli et al., 2024, *bioRxiv*, https://doi.org/10.1101/2024.08.30.609186; Guaragnella et al., 2024, *Int J Mol Sci*, https://doi.org/10.3390/ijms25073814 |


*Table: This table summarizes the current functional annotation of human SCO1 (UniProt O75880), including molecular role, localization, pathway context, disease relevance, and recent 2023-2024 developments. It is useful as a compact evidence map linking mechanistic and clinical findings to specific sources.*